{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:50:54Z","timestamp":1762102254398},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"49","license":[{"start":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T00:00:00Z","timestamp":1532908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T00:00:00Z","timestamp":1532908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22700889"],"award-info":[{"award-number":["JP22700889"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41388-018-0405-y","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T13:01:03Z","timestamp":1532955663000},"page":"6357-6367","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways"],"prefix":"10.1038","volume":"37","author":[{"given":"Yoshiya","family":"Ohno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serina","family":"Shingyoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakina","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sena","family":"Fudesaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yamawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,30]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397\u2013408.","journal-title":"Lancet"},{"key":"405_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"405_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","volume":"182","author":"BT Mossman","year":"2013","unstructured":"Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol. 2013;182:1065\u201377.","journal-title":"Am J Pathol"},{"key":"405_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413\u20139.","journal-title":"Carcinogenesis"},{"key":"405_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"405_CR6","first-page":"71","volume":"13","author":"N Nasreen","year":"2002","unstructured":"Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, et al. Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res. 2002;13:71\u201378.","journal-title":"Oncol Res"},{"key":"405_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12931-017-0546-5","volume":"18","author":"L Cortes-Dericks","year":"2017","unstructured":"Cortes-Dericks L, Schmid RA. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives. Respir Res. 2017;18:58\u201370.","journal-title":"Respir Res"},{"key":"405_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/onc.2009.478","volume":"29","author":"K Tajima","year":"2010","unstructured":"Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010;29:1941\u201351.","journal-title":"Oncogene"},{"key":"405_CR9","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/bjc.2012.519","volume":"107","author":"MA Hoda","year":"2012","unstructured":"Hoda MA, M\u00fcnzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, et al. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer. 2012;107:1978\u201386.","journal-title":"Br J Cancer"},{"key":"405_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.yexcr.2014.12.010","volume":"332","author":"JA Tamminen","year":"2015","unstructured":"Tamminen JA, Yin M, R\u00f6nty M, Sutinen E, Pasternack A, Ritvos O, et al. Overexpression of activin-A and -B in malignant mesothelioma\u2014attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth. Exp Cell Res. 2015;332:102\u201315.","journal-title":"Exp Cell Res"},{"key":"405_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2016.04.018","volume":"63","author":"MA Hoda","year":"2016","unstructured":"Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, et al. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma\u2014a multi-institutional study. Eur J Cancer. 2016;63:64\u201373.","journal-title":"Eur J Cancer"},{"key":"405_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrd4253","volume":"13","author":"DR Pattabiraman","year":"2014","unstructured":"Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells\u2014what challenges do they pose? Nat Rev Drug Discov. 2014;13:497\u2013512.","journal-title":"Nat Rev Drug Discov"},{"key":"405_CR13","first-page":"555","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Stem Cell. 2007;1:555\u201367.","journal-title":"Stem Cell"},{"key":"405_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrc2499","volume":"8","author":"JE Visvader","year":"2008","unstructured":"Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755\u201368.","journal-title":"Nat Rev Cancer"},{"key":"405_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704\u201315.","journal-title":"Cell"},{"key":"405_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2010.12.054","volume":"404","author":"FI Ghani","year":"2011","unstructured":"Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, et al. Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun. 2011;404:735\u201342.","journal-title":"Biochem Biophys Res Commun"},{"key":"405_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119549","volume":"10","author":"EA Pasdar","year":"2015","unstructured":"Pasdar EA, Smits M, Stapelberg M, Bajzikova M, Stantic M, Goodwin J, et al. Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents. PLoS ONE. 2015;10:e0119549.","journal-title":"PLoS ONE"},{"key":"405_CR18","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/onc.2011.485","volume":"31","author":"C Canino","year":"2012","unstructured":"Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene. 2012;31:3148\u201363.","journal-title":"Oncogene"},{"key":"405_CR19","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1186\/1471-2407-14-304","volume":"14","author":"L Cortes-Dericks","year":"2014","unstructured":"Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity. BMC Cancer. 2014;14:2818\u20132813.","journal-title":"BMC Cancer"},{"key":"405_CR20","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68\u20138.","journal-title":"Sci Transl Med"},{"key":"405_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.stem.2011.04.007","volume":"8","author":"E Pastrana","year":"2011","unstructured":"Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8:486\u201398.","journal-title":"Cell Stem Cell"},{"key":"405_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.yexcr.2009.03.002","volume":"315","author":"A Kultti","year":"2009","unstructured":"Kultti A, Pasonen-Sepp\u00e4nen S, Jauhiainen M, Rilla KJ, K\u00e4rn\u00e4 R, Py\u00f6ri\u00e4 E, et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res. 2009;315:1914\u201323.","journal-title":"Exp Cell Res"},{"key":"405_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.bbrc.2016.09.146","volume":"479","author":"R Liu","year":"2016","unstructured":"Liu R, Wang J-H, Xu C, Sun B, Kang S-O. Activin pathway enhances colorectal cancer stem cell self-renew and tumor progression. Biochem Biophys Res Commun. 2016;479:715\u201320.","journal-title":"Biochem Biophys Res Commun"},{"key":"405_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.stem.2011.10.001","volume":"9","author":"E Lonardo","year":"2011","unstructured":"Lonardo E, Hermann PC, Mueller M-T, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal\/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9:433\u201346.","journal-title":"Cell Stem Cell"},{"key":"405_CR25","first-page":"2431","volume":"6","author":"HA Loomans","year":"2016","unstructured":"Loomans HA, Andl CD. Activin receptor-like kinases: a diverse family playing an important role in cancer. Am J Cancer Res. 2016;6:2431\u201347.","journal-title":"Am J Cancer Res"},{"key":"405_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah LN, Chow EK-H. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2:3\u201312.","journal-title":"Clin Transl Med"},{"key":"405_CR27","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1158\/0008-5472.CAN-15-3114","volume":"76","author":"EA Turley","year":"2016","unstructured":"Turley EA, Wood DK, McCarthy JB. Carcinoma cell hyaluronan as a \u201cportable\u201d cancerized prometastatic microenvironment. Cancer Res. 2016;76:2507\u201312.","journal-title":"Cancer Res"},{"key":"405_CR28","doi-asserted-by":"publisher","first-page":"11530","DOI":"10.18632\/oncotarget.14563","volume":"8","author":"BT Preca","year":"2017","unstructured":"Preca B-T, Bajdak K, Mock K, Lehmann W, Sundararajan V, Bronsert P, et al. A novel ZEB1\/HAS2 positive feedback loop promotes EMT in breast cancer. Oncotarget. 2017;8:11530\u201343.","journal-title":"Oncotarget"},{"key":"405_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","volume":"142","author":"AN Husain","year":"2018","unstructured":"Husain AN, Colby TV, Ord\u00f3\u00f1ez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142:89\u2013108.","journal-title":"Arch Pathol Lab Med"},{"key":"405_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014640","volume":"6","author":"X Xiang","year":"2011","unstructured":"Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS ONE. 2011;6:e14640.","journal-title":"PLoS ONE"},{"key":"405_CR31","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s13277-012-0473-5","volume":"33","author":"T Hanagiri","year":"2012","unstructured":"Hanagiri T, Shinohara S, Takenaka M, Shigematsu Y, Yasuda M, Shimokawa H, et al. Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. 2012;33:2135\u201341.","journal-title":"Tumour Biol"},{"key":"405_CR32","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/0008-5472.CAN-16-2545","volume":"77","author":"S Liu","year":"2017","unstructured":"Liu S, Cheng C. Akt signaling is sustained by a CD44 splice isoform-mediated positive feedback loop. Cancer Res. 2017;77:3791\u2013801.","journal-title":"Cancer Res"},{"key":"405_CR33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc3023","volume":"11","author":"M Z\u00f6ller","year":"2011","unstructured":"Z\u00f6ller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254\u201367.","journal-title":"Nat Rev Cancer"},{"key":"405_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/cancers7010070","volume":"7","author":"HA Loomans","year":"2014","unstructured":"Loomans HA, Andl CD. Intertwining of Activin A and TGF\u03b2 signaling: dual roles in cancer progression and cancer cell invasion. Cancers. 2014;7:70\u201391.","journal-title":"Cancers"},{"key":"405_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canlet.2016.10.020","volume":"385","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis. Cancer Lett. 2017;385:215\u201324.","journal-title":"Cancer Lett"},{"key":"405_CR36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ncb3581","volume":"19","author":"KC Lin","year":"2017","unstructured":"Lin KC, Moroishi T, Meng Z, Jeong H-S, Plouffe SW, Sekido Y, et al. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat Cell Biol. 2017;19:996\u20131002.","journal-title":"Nat Cell Biol"},{"key":"405_CR37","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-12-3801","volume":"73","author":"T Hiraga","year":"2013","unstructured":"Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013;73:4112\u201322.","journal-title":"Cancer Res"},{"key":"405_CR38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1084\/jem.178.3.1103","volume":"178","author":"T Tanaka","year":"1993","unstructured":"Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. J Exp Med. 1993;178:1103\u20137.","journal-title":"J Exp Med"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0405-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0405-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0405-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:50Z","timestamp":1684617170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0405-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,30]]},"references-count":38,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0405-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,30]]},"assertion":[{"value":"1 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}